281 related articles for article (PubMed ID: 30186820)
21. Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer.
Hussung S; Akhoundova D; Hipp J; Follo M; Klar RFU; Philipp U; Scherer F; von Bubnoff N; Duyster J; Boerries M; Wittel U; Fritsch RM
BMC Cancer; 2021 Jan; 21(1):49. PubMed ID: 33430810
[TBL] [Abstract][Full Text] [Related]
22. Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer.
Court CM; Ankeny JS; Sho S; Winograd P; Hou S; Song M; Wainberg ZA; Girgis MD; Graeber TG; Agopian VG; Tseng HR; Tomlinson JS
Ann Surg Oncol; 2018 Apr; 25(4):1000-1008. PubMed ID: 29442211
[TBL] [Abstract][Full Text] [Related]
23. Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels.
Seifert AM; Reiche C; Heiduk M; Tannert A; Meinecke AC; Baier S; von Renesse J; Kahlert C; Distler M; Welsch T; Reissfelder C; Aust DE; Miller G; Weitz J; Seifert L
Oncogene; 2020 Apr; 39(15):3102-3113. PubMed ID: 32055023
[TBL] [Abstract][Full Text] [Related]
24. Strategies to improve the outcome in locally advanced pancreatic cancer.
Späth C; Nitsche U; Müller T; Michalski C; Erkan M; Kong B; Kleeff J
Minerva Chir; 2015 Apr; 70(2):97-106. PubMed ID: 25658301
[TBL] [Abstract][Full Text] [Related]
25. A nomogram based on preoperative inflammatory markers predicting the overall survival of pancreatic ductal adenocarcinoma.
Xu J; Shi KQ; Chen BC; Huang ZP; Lu FY; Zhou MT
J Gastroenterol Hepatol; 2017 Jul; 32(7):1394-1402. PubMed ID: 27973703
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
27. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
Chen T; Zhang MG; Yu XJ; Liu L
Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
[TBL] [Abstract][Full Text] [Related]
28. Laparoscopic versus open pancreatic resection for ductal adenocarcinoma: separate propensity score matching analyses of distal pancreatectomy and pancreaticoduodenectomy.
Chen K; Pan Y; Huang CJ; Chen QL; Zhang RC; Zhang MZ; Wang GY; Wang XF; Mou YP; Yan JF
BMC Cancer; 2021 Apr; 21(1):382. PubMed ID: 33836678
[TBL] [Abstract][Full Text] [Related]
29. Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas?
Rocha FG; Lee H; Katabi N; DeMatteo RP; Fong Y; D'Angelica MI; Allen PJ; Klimstra DS; Jarnagin WR
Hepatology; 2012 Oct; 56(4):1352-60. PubMed ID: 22504729
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for latent distant organ metastasis detected by staging laparoscopy in patients with radiologically defined locally advanced pancreatic ductal adenocarcinoma.
Karabicak I; Satoi S; Yanagimoto H; Yamamoto T; Hirooka S; Yamaki S; Kosaka H; Inoue K; Matsui Y; Kon M
J Hepatobiliary Pancreat Sci; 2016 Dec; 23(12):750-755. PubMed ID: 27794194
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of combined pancreas and portal vein resection in surgery for pancreatic adenocarcinoma.
Aramaki M; Matsumoto T; Etoh T; Ishio T; Himeno Y; Sasaki A; Yada K; Kawano K; Kitano S
Hepatogastroenterology; 2003; 50(49):263-6. PubMed ID: 12630036
[TBL] [Abstract][Full Text] [Related]
32. Outcome of superior mesenteric-portal vein resection during pancreatectomy for borderline ductal adenocarcinoma: results of a prospective comparative study.
Selvaggi F; Mascetta G; Daskalaki D; dal Molin M; Salvia R; Butturini G; Cellini C; Bassi C
Langenbecks Arch Surg; 2014 Jun; 399(5):659-65. PubMed ID: 24777762
[TBL] [Abstract][Full Text] [Related]
33. CKAP4, a DKK1 Receptor, Is a Biomarker in Exosomes Derived from Pancreatic Cancer and a Molecular Target for Therapy.
Kimura H; Yamamoto H; Harada T; Fumoto K; Osugi Y; Sada R; Maehara N; Hikita H; Mori S; Eguchi H; Ikawa M; Takehara T; Kikuchi A
Clin Cancer Res; 2019 Mar; 25(6):1936-1947. PubMed ID: 30610103
[TBL] [Abstract][Full Text] [Related]
34. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study.
Guo JC; Zhang P; Zhou L; You L; Liu QF; Zhang ZG; Sun B; Liang ZY; Lu J; Yuan D; Tan AD; Sun J; Liao Q; Dai MH; Xiao GG; Li S; Zhang TP
EBioMedicine; 2020 May; 55():102767. PubMed ID: 32361251
[TBL] [Abstract][Full Text] [Related]
35. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.
Sohn TA; Yeo CJ; Cameron JL; Hruban RH; Fukushima N; Campbell KA; Lillemoe KD
Ann Surg; 2004 Jun; 239(6):788-97; discussion 797-9. PubMed ID: 15166958
[TBL] [Abstract][Full Text] [Related]
36. Survivin expression and serum levels in pancreatic cancer.
Dong H; Qian D; Wang Y; Meng L; Chen D; Ji X; Feng W
World J Surg Oncol; 2015 May; 13():189. PubMed ID: 26016480
[TBL] [Abstract][Full Text] [Related]
37. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
38. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
39. The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: A Retrospective Multicenter Cohort Study.
Aziz MH; Sideras K; Aziz NA; Mauff K; Haen R; Roos D; Saida L; Suker M; van der Harst E; Mieog JS; Bonsing BA; Klaver Y; Koerkamp BG; van Eijck CH
Ann Surg; 2019 Jul; 270(1):139-146. PubMed ID: 29334554
[TBL] [Abstract][Full Text] [Related]
40. Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification.
Lindgaard SC; Sztupinszki Z; Maag E; Chen IM; Johansen AZ; Jensen BV; Bojesen SE; Nielsen DL; Hansen CP; Hasselby JP; Nielsen KR; Szallasi Z; Johansen JS
Clin Cancer Res; 2021 May; 27(9):2592-2603. PubMed ID: 33737308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
